we can pay for innovative new medicines without high drug prices and rationing

DELINKAGE IS A TERM TO DESCRIBE CHANGES IN THE WAY WE FINANCE R&D

Fund medical research and development without monopolies and high drug prices.
What is delinkage?

Eliminate monopolies

There are better ways to to fund and induce investments in R&D. We do not need legal monopolies that allow drug companies to charge high prices.

Radically lower drug prices and expand access

Instead of using the grant of monopolies and high prices as the incentive to invest in R&D, delinkage models combine expanded government funding for drug development with cash reward incentives to researchers and successful drug developers. With competition replacing monopoly, prices for products will approach marginal costs of production. We can eliminate price-sensitive formularies, expand access, and achieve better and more fair outcomes.

EFFICIENTLY Fund R&D

Under delinkage approaches, combinations of grants, subsidies, and incentives based upon cash rewards ensure robust funding for R&D. An international framework will shift from promoting monopolies and high prices to ensuring that governments can fashion cost-effective R&D incentives that target advances in life sciences and improvements in health outcomes.

Save money for consumers, taxpayers, and employers

The grant of monopolies as an inducement to invest in R&D is expensive. Delinkage alternatives cost less. Delinkage would expand access, improve health outcomes, and save money at the same time. For more information, see our page on savings.

We cannot control costs, reduce access barriers, and protect and enhance innovation unless we change the way we finance biomedical R&D. Delinkage is a radical and transformative approach to bring policy coherence to objectives regarding access, innovation, and cost control.

Latest news

Contact us for more information